NCT00402415 - Study of Combination of Sirolimus and Sutent in Patients With Advanced Solid Tumors Non-Curable With Standard Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Tumors

Interventions

DRUG

Sunitinib malate

C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off

DRUG

Rapamycin

"Dose escalation until MTD as follows:~C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly"

Trial Locations (1)

Yale Comprehensive Cancer Center at Yale University School of Medicine, New Haven